AstraZeneca Pharma India today said its board has deferred a decision on seeking shareholders approval for delisting shares from various bourses.
The company's board, in a meeting held today, deferred consideration of seeking approval of shareholders of the company through postal ballot for the delisting of equity shares of the company proposed by the promoters, AstraZeneca Pharma India said in a filing to the BSE.
The matter has been deferred in light of discussions with ICICI Securities Ltd, the manager and Walker Chandoik & Co LLP, the valuer and pending their response to the clarifications and explanations sought from them, it added.
Last week, the company had fixed the floor price at Rs 854.1 apiece for delisting its shares from stock exchanges.
AstraZeneca Pharmaceuticals AB, Sweden, holds 75 per cent stake in AstraZeneca Pharma India.
Last month, AstraZeneca Pharma had received by email a letter from the promoter proposing to make a voluntary delisting offer to the public shareholders from stock exchanges.
The company on March 18 had announced that its board approved delisting of the company's shares from bourses.
Shares of the company today closed at Rs 1,062.10 a share on the BSE, down 2.81 per cent from its previous close.
